Reunion is a clinical-stage biopharmaceutical company developing innovative therapeutics for underserved mental health disorders. Our lead program, luvesilocin, is a clinically validated, purpose-designed, 5-HT2A agonist advancing through a deliberate development strategy intended to generate learnings across mood and anxiety disorders, inform future indications, and maximize long-term patient impact.
We envision a day when depression and other mental health conditions aren’t just disorders that can be managed, but instead are curable. We relentlessly pursue the development of safer therapeutics that provide durable antidepressive effects for the millions of people whose needs are not met by the current standard of care.
RECENT NEWS AND MEDIA COVERAGE
June 15, 2026: Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
May 11, 2026: Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings
February 23, 2026: U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
Leading with Bold Science
Our lead clinical-stage drug candidate, luvesilocin, is a proprietary, short-duration, patented prodrug of 4-OH-DiPT designed to combine the therapeutic potential of psychedelics with practical treatment attributes that may support broad clinical adoption. Through activation of the serotonin 2A receptor (5HT2AR), luvesilocin is designed to leverage neuroplasticity mechanisms believed to contribute to durable therapeutic benefit.
Experience, Meet Innovation
Reunion’s team consists of industry leaders and scientific experts with deep experience in every aspect of neuroscience pharmaceutical drug development. We’re blazing the path to create a transformative new generation of therapeutics to create a world where mental and emotional wellbeing is the baseline.